Astrazeneca Stock News

AstraZeneca Plc (NASDAQ: AZN) said the U.S. government has agreed to purchase an additional 500,000 doses of its antibody cocktail, Evusheld, used to prevent COVID-19. The Company said the delivery

AstraZeneca Plc (NASDAQ: AZN) has posted preliminary data from an ongoing safety and immunogenicity trial of its COVID-19 shot, Vaxzevria. When given as a third booster dose, the data showed that i

AstraZeneca Plc (NASDAQ: AZN) has signed a collaboration agreement with Scorpion Therapeutics to discover, develop and commercialize precision medicines against previously hard-to-target cancer p

https://www.investing.com/news/stock-market-news/astrazeneca-says-us-to-buy-additional-500000-evusheld-doses-2737283

DUBLIN , Jan. 12, 2022 /PRNewswire/ -- The "Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021" report has been added to ResearchAndMarkets.com''s offering. The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014- 2021 report provides comprehensive access to available deals and contract documents for over 2,900 clinical stage deals. The report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector. Understanding the flexibility of a prospective partner''s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

It's not too late to invest in this dynamic area.

Fusion Pharmaceuticals (FUSN) has surged around 4% in after-hours trading session, after announcing the nomination of the first targeted alpha therapy ((TAT)) candidate under

AstraZeneca (AZN) inks collaboration and license agreement with Neurimmune AG to develop/commercialize the latter's NI006 for treating transthyretin amyloid cardiomyopathy.

Some of the world's biggest drugmakers have important dates with the FDA coming up soon.

A cash-rich business can mean less risk of dilution for investors.

AstraZeneca PLC (LSE:AZN) said it entered into a collaboration with Neurimmune AG for NI006, an investigational human monoclonal antibody currently in Phase Ib development for the treatment of transth

Welcome to Wednesdays Overnight Health Care, where were following the latest moves on policy and news affecting your health. Subscribe here: thehill.com/newsletter-signup. COVID-19 sniffing dogs are making the rounds

The company is riding an unstoppable long-term trend: strong demand for lifesaving medicines.

AstraZeneca (AZN) closes its agreement with Ionis for jointly developing and commercializing eplontersen in the United States.

Dr. Anthony Fauci, White House chief medical advisor, joins 'Closing Bell' to talk about his thoughts on anti-vaxxers, the Covid testing kit shortage and further guidelines for the travel industry as